<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1432">
  <stage>Registered</stage>
  <submitdate>9/01/2007</submitdate>
  <approvaldate>9/01/2007</approvaldate>
  <nctid>NCT00421304</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized With RSV Illness</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MI-CP141</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Respiratory Syncytial Virus (RSV)</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Motavizumab
Other interventions - Biological/Vaccine: Motavizumab
Other interventions - Placebo

Experimental: 1 - MEDI-524 or Motavizumab

Experimental: 2 - MEDI-524 or Motavizumab

Placebo Comparator: 3 - Placebo


Other interventions: Motavizumab
Will receive a single dose of IV of Motavizumab (100mg/kg)

Other interventions: Biological/Vaccine: Motavizumab
A single IV dose of placebo (30 mg/kg).

Other interventions: Placebo
A single IV dose of placebo (30 or 100 mg/kg).

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Description of Motavizumab levels and viral load in the upper respiratory tract after a single 30 mg/kg or 100 mg/kg IV dose of Motavizumab in children who are hospitalized with RSV infection. (Viral cultures and RT-PCR)</outcome>
      <timepoint>September 2009</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Length (from randomization) of hospitalization after Motavizumab or placebo is used to treat RSV illness in hospitalized children</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate effect of Motavizumab on severity of RSV illness during hospitalization</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The frequency of medically-attended wheezing in the 12 months following randomization as measured by documented events of wheezing that are evaluated by a healthcare provider</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Summary of Motavizumab serum levels and the number and percentage of patients with detectable anti-Motavizumab antibodies (PK and immunogenicity assays)</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Describe the effect of Motavizumab on markers of inflammation as measured by gene microarray and cytokine levels</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of Motavizumab as measured by adverse or serious adverse events through Study Day 90 and Serum chemistry, complete blood count (CBC), and platelets at baseline and at Study Days 7 and 30.</outcome>
      <timepoint>September 2009</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children must meet all of the following criteria:

          -  Previously healthy

          -  Age less or equal to 12 months at the time of randomization

          -  Gestational age more or equal to 36 weeks

          -  Hospitalized for lower respiratory tract illness (i.e., RSV bronchiolitis and/or
             pneumonia)

          -  Documented positive RSV test within 48 hours prior to randomization

          -  Randomization within 12 hours of the decision to hospitalize a child for RSV illness

          -  Written informed consent obtained from the patient's parent(s)/legal guardian</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Children must have none of the following:

          -  Prior receipt of or receiving ribavirin or other anti-viral treatment for the current
             episode of RSV infection prior to randomization

          -  Any use of systemic or inhaled steroids within the past 30 days prior to randomization

          -  Intubation for ventilatory support at randomization

          -  Any medically significant underlying ongoing chronic illness or organ system
             dysfunction, or other known acute illness except for RSV infection

          -  Known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or
             other neurologic disorder or immunodeficiency

          -  Requirement for supplemental oxygen at any time prior to the current RSV infection
             (brief use of oxygen in the immediate postnatal period to treat a transient condition
             is allowed)

          -  Mechanical ventilation at any time prior to the onset of the current RSV infection

          -  Congenital heart disease [children with medically or surgically closed patent ductus
             arteriosis (PDA), small atrial septal defect (ASD) or small ventricular septal defect
             (VSD) will be allowed]

          -  Previous reaction to IVIG, blood products, or other foreign proteins

          -  Prior use of IVIG, palivizumab (Synagis√í), or other immunoglobulin products within the
             past 2 months

          -  Currently receiving other investigational agents or have received any other
             investigational agents within the 3 months prior to randomization

          -  Prior or current participation in any investigational study with a therapeutic agent
             or vaccine for RSV</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>118</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Research Site - Herston</hospital>
    <postcode>4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>West Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Panama</country>
      <state>Ciudad de Panama</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to describe the effect of a single dose of medication
      compared to placebo in the upper respiratory tract in previously healthy children less than
      or equal to 12 months of age who are hospitalized with lower respiratory tract illness.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00421304</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>M. Pamela Griffin, M.D.</name>
      <address>MedImmune LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>